Respiratory Syncytial Virus (RSV) Therapeutics Market Size to Exceed $4.59 Billion by 2029 | Growth and Industry Trends
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Respiratory Syncytial Virus (RSV) Therapeutics Market Grown from 2024 to 2025?
In recent times, there has been a significant growth in the size of the respiratory syncytial virus (RSV) therapeutics market. The market, which stands at $1.6 billion in 2024, is projected to escalate to $2 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 25.0%. The expansion during the historical period is associated with increased awareness of the disease, advanced virology, risk in children, epidemic occurrences, and the development of vaccines.
What Growth Rate Is Anticipated for the Respiratory Syncytial Virus (RSV) Therapeutics Market in the Coming Years?
Expectations are high for the respiratory syncytial virus (RSV) therapeutics market size to witness a significant upswing in the coming years, with projections of reaching approximately $4.59 billion by 2029, growing at a CAGR of 23.1%. The growth during the forecast period is primarily due to aspects such as the advent of biologic therapies, the introduction of new antivirals, a heightened focus on the aged populace, strategies centering maternal immunization, as well as international research partnerships. The forecast period will also showcase noteworthy trends including progression in monoclonal antibodies, developments in nasal vaccines and delivery systems, the utilization of combination therapies, the introduction of cutting-edge drug delivery systems, and the rise of home-administered treatment options.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12601&type=smp
Who Are the Leading Companies in the Respiratory Syncytial Virus (RSV) Therapeutics Market?
Major companies operating in the respiratory syncytial virus (RSV) therapeutics market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Regeneron Pharmaceuticals Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd., Bavarian Nordic A/S, SciClone Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc., Ascletis Pharma Inc., NanoBio Corporation, Vaxart Inc., Ark Biosciences Private Limited, Pulmocide Ltd
What Are the Key Drivers of the Respiratory Syncytial Virus (RSV) Therapeutics Market?
An upsurge in the incidence of RSV infection escalates the expansion of the respiratory syncytial virus (RSV) therapeutics market. RSV is a common respiratory disease that leads to mild to serious respiratory infections, particularly in infants, young kids, elderly people, and those having weak immune systems. The growing cases of RSV infections necessitate the evolution of innovative treatments to meet the increasing demand and lessen the impact of RSV-related complications. To exemplify, in September 2023, the Centres for Disease Control and Prevention, a national public health agency based in the US, reported a substantial rise in the rate of hospitalizations linked to RSV among children less than 4 years, soaring from 2.0 hospitalizations per 100,000 population for the week ending August 5, 2023, to 7.0 hospitalizations per 100,000 population by August 19, 2023. Consequently, the surge in the RSV infection prevalence boosts the growth of the respiratory syncytial virus (RSV) therapeutics market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12601&type=smp
What Are the Key Market Segments in the Respiratory Syncytial Virus (RSV) Therapeutics Industry?
The respiratory syncytial virus (RSV) therapeutics market covered in this report is segmented –
1) By Drug: Palivizumab, Ribavirin, Other Drugs
2) By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications
3) By Dosage Form: Oral, Injectable, Other Dosage Forms
4) By Patient Type: Pediatrics, Adults
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Palivizumab: Monoclonal Antibody
2) By Ribavirin: Antiviral Medication
3) By Other Drugs: Cidofovir, Nitazoxanide, Other Experimental Or Off-Label Treatments
What Are the Latest Trends in the Respiratory Syncytial Virus (RSV) Therapeutics Market?
The emergence of enhanced vaccines and drugs is a significant trend captivating the respiratory syncytial virus (RSV) therapeutics market. The primary businesses in this market are concentrating their efforts on creating these innovative solutions to maintain their market standing. A prime example is Pfizer Inc., a US-based pharmaceutical manufacturing firm who, in May 2023, obtained approval from the Food and Drug Administration – a federal agency dedicated to preserving and enhancing public health – for ABRYSVO. This bivalent RSV prefusion F (RSVpreF) vaccine ABRYSVO (Respiratory Syncytial Virus Vaccine) is employed to thwart lower respiratory tract illnesses trigged by RSV in individuals aged 60 and up. It consists of a duo of preF proteins designed to boost immunity against RSV A and B types, and its safety and effectiveness have been confirmed clinically.
Access The Full Report Here:
What Are the Key Regional Markets in the Respiratory Syncytial Virus (RSV) Therapeutics Industry?
North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (RSV) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12601
This Report Delivers Insight On:
1. How big is the respiratory syncytial virus (rsv) therapeutics market, and how is it changing globally?
2. Who are the major companies in the respiratory syncytial virus (rsv) therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the respiratory syncytial virus (rsv) therapeutics market right now?
4. Which products or customer segments are growing the most in the respiratory syncytial virus (rsv) therapeutics market?
5. What factors are helping or slowing down the growth of the respiratory syncytial virus (rsv) therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
